A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT07650266
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Nasopharyngeal Cancer
  • Nasopharyngeal Carcinoma
  • Nasopharynx Cancer
  • Nasopharynx Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cemiplimab — DRUG
    Cemiplimab (LIBTAYO) is a PD-1 blocking antibody
  • Fianlimab — DRUG
    Fianlimab is a fully human monoclonal antibody targeting the immune checkpoint receptor LAG-3 on T cells

Study Details

The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.

Key Dates

Start date
Jul 31, 2026
Status verified
Jun 2026
Primary completion
Jul 31, 2030
Completion
Jul 31, 2030

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Induction Therapy: Cemiplimab alone
    Participant will undergo induction therapy (cemiplimab alone or cemiplimab + fianlimab) after screening and randomization is complete
  • Active Comparator: Induction Therapy: Cemiplimab + Fianlimab
    Participant will undergo induction therapy (cemiplimab alone or cemiplimab + fianlimab) after screening and randomization is complete

Primary Outcome Measure

Complete response rate [ Time Frame: 4 months ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking RidgeNew Jersey07920
Nancy Lee, MD
212-639-3341
Memorial Sloan Kettering Monmouth (Limited protocol activities)MiddletownNew Jersey07748
Nancy Lee, MD
212-639-3341
Memorial Sloan Kettering Bergen (Limited Protocol Activities )MontvaleNew Jersey07645
Nancy Lee, MD
212-639-3341
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)CommackNew York11725
Nancy Lee, MD
212-639-3341
Memorial Sloan Kettering Westchester (Limited protocol activities)HarrisonNew York10604
Nancy Lee, MD
212-639-3341
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Nancy Lee, MD
212-639-3341
Memorial Sloan Kettering at Nassau (Limited Protocol Activities)UniondaleNew York11553
Nancy Lee, MD
212-639-3341

Find similar trials in Basking Ridge, NJ

By research site
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited protocol activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities )· Montvale, NJMemorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)· Commack, NYMemorial Sloan Kettering Westchester (Limited protocol activities)· Harrison, NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY

Related Studies